Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders

Biomedicine and Pharmacotherapy

Volumn 50, Issue 8, 1996, Pages 376-382

  Sagripanti, A ^a,b   Ferretti, A ^a   Nicolini, A ^a   Carpi, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Bleeding; Essential thrombocythemia; Picotamide; Platelet function; Polycythemia vera; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BUSULFAN; HYDROXYUREA; MELPHALAN; PICOTAMIDE; PIPOBROMAN;

ADULT; AGED; BLEEDING; COLOR ULTRASOUND FLOWMETRY; CONFERENCE PAPER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0029833824     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(96)89672-7     Document Type: Conference Paper

References (53)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L . Polycythemia vera. Stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913
2. Balduini CL. Primary thrombocythemia: new drugs for an evolving disease. Haematologica 1992;77:297
3. Barbui T, Cortellazzo S, Viero P, Bassan R, Dini E, Semezaro N. Thrombohaemorrhagic complication in 101 cases of myeloproliferative disorders. Relationship to platelet number and function. Eur J Cancer Clin Oncol 1983;19:1593-99
4. Barbui T, Buelli M, Cortellazzo S et al. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987;33:265
5. Bellucci S, Janvier M, Tobelem G et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986;58:2440-47
6. Berlin NJ. Diagnosis and classification of the polycythemias. Semin Haematol 1975;12:339-51
7. Budde U, Schaefer G, Mueller N et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981-5
8. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962;172:513-20
9. Colombi M, Radaelli F, Zocchi L, Maido AT. Thrombotic and haemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67:2926-30
10. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-36
11. Cortelazzo S, Viero P, Finazzi G, D'Emilio, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62
12. Davis RB. Acute thrombotic complications of myeloproliferative disorders in young adults. Am J Clin Pathol 1985;84:180-85
13. Dai CH, Krantz SD; Dessypris EN, Means RT, Horn ST, Gilbert HS. Polycythemia vera II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80:891-99
14. 2 in the differential diagnosis of primary versus secondary thrombocytosis. Thromb Haemostas 1989;62:570
15. Fattori B, De Ciccio M, Casani A, Casalino F, Sagripanti A, Ghilardi PL. Vestibular disorders in primary thrombocythemia. Biomed & Pharmacother 1993;47:287
16. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-56
17. Fialkow P, Faguet G, Jacobson R, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-19
18. Gresele P. Van Houtte E, Arnout J et al. Thromboxane synthase inhibition combined with thromboxane receptor blockade. A step forward in antithrombotic strategy. Thromb Haemostas 1984;52:364
19. Grossi A, Rossetti S, Vannucchi A, Rafanelli D, Rossi Ferrini P. Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders. A retrospective study of 118 patients. Clin Lab Haematol 1988;10:167-75
20. Hattori A, Nagayama R, Kishi K et al. Essential thrombocythemia in Japan. A survey of 225 patients. Leuk Lymph 1991;4:177-82
21. Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988;61:2487-96
22. Hoagland H, Silverstein MN. Primary thrombocythemia in the young patients. Mayo Clin Proc 1978;53:578-80
23. Iland HJ, Laszlo J, Peterson P et al. Essential thrombocythemia. Clinical and laboratory characteristics at presentation. Trans Assoc Phys 1983;96:165
24. Jabaily J, Iland HJ, Laszlo J et al. Neurologic manifestations of essential thrombocythemia. Ann Int Med 1983;99:513-18
25. Kessler CM, Klein HG, Havlik J. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982;50:157-67
26. Hussain S, Schwartz JM, Friedman SA, Chua SN. Arterial thrombosis in essential thrombocythemia. Am Heart J 1978;96:31-6
27. Marchi S, Polloni A, Paparo M et al. Endoscopic picture of upper digestive tract in chronic myeloproliferative disorders. In: Sagripanti A, Carpi A, Grassi B, eds. Advances in Management of Malignancies. Bologna: Monduzzi, 1988;561-70
28. McIntyre KJ, Hoagland HC, Silverstein MN et al. Essential thrombocythemia in young adults. Mayo Clin Proc 1991;66:149-54
29. Michiels JJ, Abels J, Steketee J, Van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-71
30. Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-10
31. Mitus AJ, Barbui T, Shulman LN et al. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990;88:371-75
32. Murphy S. Thrombocytosis and thrombocythemia. Clin Haematol 1975;12:89-106
33. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Sem Hematol 1986;23:177-82
34. Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979;54:1258-71
35. Pagliuca A, Mufti GJ, Janossa-Thaernia M et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis. Possible evidence of an occult myeloproliferative state. Quart J Med 1990;281:981-89
36. Pearson TC. Primary thrombocythemia: diagnosis and management. Br J Haematol 1991;78:145
37. Preston FE, Emmanuel IG, Winfield IG, Malia RG. Essential thrombocythemia and peripheral gangrene. Br Med J 1974;III:548-52
38. Randi ML, Casonato A, Fabris F, Vio C, Girolami A. The significance of thrombocytosis in old age. Acta haematol 1987;78:41-4
39. Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992;77:402-04
40. Sagripanti A, Ammannati P, Polloni A, Grassi B. Picotamide as antithrombotic agent in myeloproliferative disorders: result of a clinical study. In: Advances in Management of Malignancies. Sagripanti A, Carpi A, Grassi B, eds. Bologna: Monduzzi, 1988;577-88
41. Sagripanti A, Grassi B. Picotamide as antithrombotic agent in myeloproliferative disorders: rationale and experimental design. In: Sagripanti A, Carpi A, Grassi B, eds. Advances in Management of Malignancies. Bologna: Monduzzi, 1988;565-76
42. Sagripanti A, Riyhai R, Nicolini A, Henze V, Carpi A. Thromboembolism in cancer patients. Intern Med Clin Lab 1993;1:117-28
43. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Intern Med Clin Lab 1993;1:109-15
44. Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med. 1982;306:381-6
45. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-12
46. Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. A new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-94
47. Singh AK, Wetherley-Mein G. Microvascular occlusive lesions in primary thrombocythaemta. Br J Haematol 1977;36:553-64
48. Spaet T, Lejniekes T, Gaynor E. Defective platelets in essential thrombocythemia. Arch Intern Med 1969;124: 135-41
49. Teofili L, De Stefano V, Leone G et al. Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemostas 1992;67:297-301
50. Valla D, Casadevall N, Huisse MG et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94:1063-69
51. Valla D, Casadevall N, Lacombe C et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-34
52. Van de Pette JEW, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G . Primary thrombocythaernia treated with busulphan. Br J Haematol 1986;62:229-37
53. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198-203